RUNX1异常诱导SPATS2L促进急变期CML生长存活与应激颗粒组装
该研究探讨RUNX1异常在急变期慢性髓性白血病(BP-CML)中的转录后调控机制。通过有机相分离鉴定RUNX1缺陷BP-CML细胞的RNA结合蛋白组,发现SPATS2L表达及RNA结合活性被诱导,促进应激颗粒组装和细胞生长存活;抑制SPATS2L可增加高三尖杉酯碱(HHT)敏感性,提示SPATS2L介导治疗抵抗。
要点
- RUNX1缺陷或表达RUNX1::EVI1的BP-CML细胞中SPATS2L表达及RNA结合活性升高。
- SPATS2L缺失减少应激颗粒组装并抑制多个BP-CML细胞系生长存活。
- HHT可消除RUNX1缺陷BP-CML细胞的应激颗粒组装,RUNX1突变原代细胞对HHT更敏感。
核心结论
- RUNX1异常通过诱导SPATS2L促进BP-CML细胞生长、存活和应激颗粒组装。
- SPATS2L可能贡献RUNX1突变CML的治疗抵抗,应激颗粒或广泛参与TKI抵抗。
研究设计与样本
- 利用正交有机相分离表征RUNX1缺陷BP-CML细胞的RNA结合蛋白组。
- 在BP-CML细胞系及原代细胞中研究RUNX1缺失或RUNX1::EVI1表达对SPATS2L和应激颗粒的影响。
主要发现
- RUNX1缺陷BP-CML细胞中参与应激反应及翻译/核糖体生物发生的RNA结合蛋白显著改变。
- RUNX1缺失或RUNX1::EVI1表达诱导SPATS2L表达和RNA结合活性。
- SPATS2L缺失减少应激颗粒组装并抑制多个BP-CML细胞系生长/存活。
- HHT消除RUNX1缺陷BP-CML细胞的应激颗粒组装,RUNX1 LOF/亚效突变原代BP-CML细胞优先对HHT敏感。
- 抑制SPATS2L降低应激颗粒形成能力并增加RUNX1缺陷BP-CML细胞对HHT的敏感性。
临床怎么用
- 对于RUNX1异常的BP-CML,SPATS2L/应激颗粒轴可能是潜在治疗靶点。
- HHT可能优先用于携带RUNX1 LOF/亚效突变的BP-CML患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RUNX1 is a critical regulator of hematopoiesis. In CML, somatic RUNX1 mutations and RUNX1::MECOM/EVI1, are associated with TKI resistance and progression to BP-CML. To examine post-transcriptional dysregulation downstream of RUNX1 aberrations, we used orthogonal organic phase separation to characterise the RNA-binding proteome of RUNX1 deficient BP-CML cells. RUNX1 depleted BP-CML cells exhibited significant alterations to RBPs involved in stress response pathways and translation/ribosome-biogenesis. Furthermore, RUNX1 depletion or expression of RUNX1::EVI1 in BP-CML cells induced expression and RNA binding activity of SPATS2L, a component of stress granules (SG). Whilst RUNX1 depletion increased SG-assembly, SPATS2L depletion reduced SG-assembly and inhibited the growth/survival of multiple BP-CML cell lines. Homoharringtonine (HHT), used historically in TKI-resistant CML, ablated SG-assembly in BP-CML cells with RUNX1 depletion, and primary BP-CML cells with LOF/hypomorphic RUNX1 mutations were preferentially sensitised to HHT. Suppressing SPATS2L expression induced by RUNX1 depletion, reduced SG-forming capacity and increased the HHT-sensitivity of RUNX1 depleted BP-CML cells, suggesting SPATS2L contributes to therapeutic resistance in RUNX1 mutated CML. Finally, we demonstrate that SGs may contribute more widely to TKI-resistance in this setting. This study suggests that SPATS2L/SG induction could be critical to RUNX1-mutant leukemias, and, provides preliminary evidence for a mutationally-targeted approach in CML with RUNX1 aberrations.
引用
- Palmer DA, Ogilvie-Park D, Muir AL, et al. RUNX1 aberrations in blast-phase chronic myeloid leukaemia induce the RNA-binding protein SPATS2L, which promotes growth, survival and stress granule assembly. Leukemia. 2026. PMID: 42855471. doi:10.1038/s41375-026-03161-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。